IAPP peptide, pharmaceutical composition containing IAPP peptide and application of IAPP peptide

By developing peptide variants of IAPP, especially the peptides of Weedel seals, raccoons and chickens, the aggregation and cytotoxicity of human IAPP have been successfully inhibited, providing an effective treatment plan for type 2 diabetes, and solving the difficulty in inhibiting IAPP in the prior art The toxicity problem significantly improves disease progression and health status.

CN118955675APending Publication Date: 2024-11-15LOYOLA MARYMOUNT UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410844356.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-02-22
Filing Date
2020-02-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The aggregation of the amyloid peptide IAPP in type 2 diabetes is related to cytotoxicity. The prior art is difficult to effectively inhibit its toxicity, resulting in disease progression and high economic and social costs.

Method used

A series of IAPP peptide variants, including peptides from Weedel seals, raccoons and chickens, have the ability to inhibit human IAPP aggregation and protect cells from toxicity, used as pharmaceutical compositions to treat amyloid diseases.

Benefits of technology

These IAPP peptide variants significantly inhibit IAPP aggregation and cytotoxicity, providing potential therapeutic strategies to slow diabetes progression and improve patient health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004915293430000101
    Figure BDA0004915293430000101
  • Figure BDA0004915293430000111
    Figure BDA0004915293430000111
  • Figure HDA0004915293440000011
    Figure HDA0004915293440000011
Patent Text Reader

Abstract

The present invention relates to an IAPP peptide, a pharmaceutical composition comprising the same, and an application thereof, and more specifically, to an IAPP peptide represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 42-46, which inhibits aggregation of human islet amyloid polypeptides and inhibits formation of amyloid fibrils.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application. The international application number of the original application is PCT / US2020 / 019557, the Chinese national application number is 202080015845.1, the application date is February 24, 2020, and the name of the invention is “Variants of amyloid peptides”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Patent Application No. 62 / 809,167, filed on February 22, 2019, entitled AMYLOID PEPTIDE VARIANTS FOR THE TREATMENT OF DIABETES. Technical Field

[0004] The present invention relates to IAPP peptide, a pharmaceutical composition containing the same and use thereof. Background Art

[0005] Many proteins are known to adopt alternative, misfolded structures that may be associated with various diseases. Proteins such as human islet amyloid polypeptide (hIAPP, amylin) in type 2 diabetes, Aβ42 in Alzheimer's disease, and α-synuclein in Parkinson's disease are all known to misfold and aggregate into toxic oligomers and fibrils. While it is known that these misfolded proteins are toxic to cells, the exact role they play in the progression of these diseases remains a mystery.

[0006] Amyloid diseases pose a serious threat to human health. Over the past decade, the economic and social costs associated with type 2 diabetes have been well documented. The American Diabetes Association estimates that 25.8 million children and adults in the United States have diabetes, approximately 8.3% of the population, with nearly 2 million new cases diagnosed each year. Because the incidence of this disease increases with age, the number of people with type 2 diabetes will increase as our population ages. If no treatment is found to prevent or slow the progression of this disease, it is estimated that as many as 100 million Americans alone could be affected by diabetes within the next 40 years, with an estimated cost of more than $174 billion per year. In 2008, the United States spent $116 billion on direct medical costs, with an additional estimated $58 billion in indirect costs from work loss, disability, and premature death.

[0007] Although obesity is a clear factor associated with type 2 diabetes, more than 70% of obese people do not develop diabetes, suggesting that other factors influence the progression of this disease. One possible factor associated with the progression of type 2 diabetes is the aggregation of an amyloid peptide, islet amyloid polypeptide (IAPP). This 37 amino acid polypeptide is co-secreted with insulin by the beta islet cells of the pancreas. During the development of type 2 diabetes, IAPP aggregates into various different amyloid states. As is known, IAPP is found as extracellular amyloid deposits in more than 90% of patients with the disease.

[0008] The link between IAPP aggregation and diabetes also appears to extend to non-humans. Like humans, cats and primates can develop diabetes. Also like humans, cats and primates express IAPP variants that aggregate and form toxic amyloids. In contrast, rat, mouse and hamster IAPP variants do not aggregate or form toxic amyloids. Rats, mice and hamsters do not spontaneously develop diabetes. However, when mice and rats are engineered to express human IAPP, they do develop type 2 diabetes and symptoms associated with the disease.

[0009] It has recently been proposed that one form of IAPP may adopt a cylindrical fold. While the structure of the IAPP molecules that form aggregates remains to be determined, it is clear that some of these aggregates are highly toxic to cells. Studies have shown that synthetic IAPP can act as a highly toxic agent in vitro when added to human pancreatic beta cells as well as various other mammalian cell lines. IAPP is found in approximately 90% of patients with type 2 diabetes in the form of extracellular deposits of amyloid protein. IAPP has also been shown to be a toxic agent in vitro when added to mammalian cells. While it is not yet clear how the self-assembly of IAPP leads to the development of the disease, recent studies have shown that the formation of low-order protein aggregates (two to ten self-assembling proteins) leads to cellular toxicity and ultimately to the development of the disease. Summary of the invention

[0010] We have recently identified a series of IAPP peptides that inhibit the aggregation of human IAPP and rescue mammalian cells from the toxicity of hIAPP. These IAPP variants are effective inhibitors of hIAPP aggregation and can be used as therapeutic agents and probes to understand the fundamental toxicity of amyloid. The IAPP peptides of the present invention have an amino acid sequence selected from one of the following sequences:

[0011] a) SEQ ID NO: 15-18,

[0012] b) SEQ ID NO: 26-37,

[0013] c) SEQ ID NO:42-46,

[0014] d) SEQ ID NO: 53-64, and

[0015] e) SEQ ID NO:65-68.

[0016] These peptides include peptides mutated from Weddell seal IAPP (SEQ ID NOs: 15-18), raccoon IAPP (SEQ ID NOs: 26-37 and SEQ ID NOs: 42-46), and chicken IAPP (SEQ ID NOs: 53-64 and SEQ ID NOs: 65-68). In some embodiments, preferred sequences include SEQ ID NOs: 16-17 (WS_RL and WS_RP); SEQ ID NO: 46 (Rac_L26Y); SEQ ID NOs: 31-34 (R1-27 to R1-30); SEQ ID NOs: 66-68 (Chv16L, ChI22L, ChY26L); and SEQ ID NOs: 59-61 (C1-27 to C1-29).

[0017] The above-mentioned IAPP peptides can be used to inhibit the aggregation of hIAPP in vitro or in vivo. In one embodiment, these peptides can be used to treat amyloid diseases, such as diabetes. When used for therapeutic applications, the IAPP peptides can be combined with one or more pharmaceutically acceptable excipients to form a pharmaceutical composition.

[0018] IAPP peptides naturally occurring in cats, dogs, chickens, polar bears, raccoons and Weddell seals can also be used to treat amyloid diseases and inhibit hIAPP aggregation. These peptides may have a sequence selected from SEQ ID NO: 2-7. Raccoon and chicken IAPP peptides are preferred.

[0019] Therefore, the IAPP peptide of the present invention can be used in a method for treating a subject suffering from an amyloid disease, the method comprising the step of administering an IAPP peptide to a subject in need thereof, wherein the IAPP peptide has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-7, SEQ ID NOs: 15-18, SEQ ID NOs: 26-37, SEQ ID NOs: 42-46, SEQ ID NOs: 53-64, and SEQ ID NOs: 65-68. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a table comparing human IAPP and various animal IAPPs. Amino acids that differ from hIAPP are in bold.

[0021] Figure 2is a graph showing the results of Thioflavin T binding assays in which human IAPP was mixed with IAPP from other species. The graph shows the average of at least three experiments, and the error bars represent the standard deviation between experiments.

[0022] Figure 3 Results of atomic force microscopy (AFM) scans of IAPP variants are shown. 37 μM human IAPP was mixed with 75 μM of each animal IAPP and the samples were incubated at 37°C for 40 minutes with shaking. All scans show the original data without flattening and are 10 μm x 10 μm.

[0023] Figure 4 is a graph showing the results of the MTT viability assay. The leftmost black bar shows the average cell viability alone. The left bar above each species identifier on the horizontal axis (raccoon, chicken, etc.) shows the average cell viability after the addition of 12.8 μM hIAPP or animal IAPP variants alone. The right bar above each species identifier on the horizontal axis shows the cell viability after hIAPP was mixed with each animal IAPP variant (a 1:1 ratio of hIAPP to 12.8 μM mixture of each designated animal IAPP). The asterisk shows a significant increase in cell viability between hIAPP alone and hIAPP mixed with raccoon or chicken IAPP variants.

[0024] Figure 5 Results of AFM scans of the materials are shown. Samples labeled with hIAPP contained 40 μM hIAPP. Samples with Pramlintide and hIAPP contained a 2:1 molar mixture (80 μM Pramlintide mixed with 40 μM hIAPP). Samples with raccoon IAPP and Pramlintide alone contained 40 μM of the peptides. Each sample was incubated with shaking for 40 minutes at 37°C under conditions known to promote hIAPP amyloid formation. All scans show the raw data without flattening and are 10 μm x 10 μm.

[0025] Figure 6 is a graph showing the results of MTT viability assay. The left bar shows the average viability of individual cells. The left bar above each peptide identifier on the horizontal axis shows the average cell viability after adding 12.8 μM hIAPP or IAPP variants (variants indicated on the horizontal axis) alone. The right bar above each peptide identifier on the horizontal axis shows the cell viability after hIAPP is mixed with each IAPP variant (each IAPP to 12.8 μM hIAPP ratio is 1:1).

[0026] Figure 7is a table listing the amino acid sequences of variants of seal IAPP that were tested for their inhibitory potential against hIAPP amyloid formation. Peptides that inhibit hIAPP amyloid formation are indicated by a bold "yes" in the "inhibition" column, while peptides that rescue cells from hIAPP toxicity are indicated by a bold "yes" in the "rescue" column.

[0027] Figure 8 is a graph showing the results of Thioflavin T binding assay when hIAPP was mixed with the indicated Weddell seal IAPP peptide variants. Data show the mean of at least three experiments, and the error bars show the standard deviation between experiments.

[0028] Fig. 9 AFM images of hIAPP mixed with the indicated Weddell seal IAPP variants are shown. All scans show raw data without flattening and are 10 μm x 10 μm.

[0029] Fig.10 : is a graph showing the results of the MTT survival assay. The leftmost black bar shows the average survival rate of individual cells. The left bar above each peptide identifier (WS, WS-R, etc.) on the horizontal axis represents the average cell survival rate after adding 12.8 μM hIAPP or Weddell seal IAPP variant peptide alone. The right bar above each peptide identifier on the horizontal axis shows the cell survival rate of hIAPP mixed with Weddell seal IAPP variant (mixture of hIAPP and Weddell seal IAPP at a ratio of 1:1 12.8 μM).

[0030] Fig.11 is a table listing several peptides based on truncations of the full-length raccoon IAPP sequence. Peptides that inhibit hIAPP amyloid formation are indicated by a bold "Yes" in the "Inhibition" column, while peptides that rescue cells from hIAPP toxicity are indicated by a bold "Yes" in the "Rescue" column.

[0031] Fig.12 is a graph showing the results of the Thioflavin T binding assay when hIAPP was mixed with the indicated raccoon IAPP variants. Human IAPP was incubated with each designated peptide at 37°C with shaking. The four vertical bars for each peptide represent the fluorescence after 10 minutes, 20 minutes, 25 minutes, and 30 minutes from left to right, respectively. The data show the average of at least two experiments, and the error bars show the standard deviation between experiments.

[0032] Fig.13 is described for the raccoon IAPP truncation mutant Fig.12 The four vertical bars for each of the four peptides represent fluorescence after 10, 20, 25, and 30 minutes, respectively, from left to right (the native raccoon IAPP on the left side of the graph does not include the 30 minute reading).

[0033] Fig.14 is a table listing several peptides based on raccoon IAPP sequence mutations. Peptides that inhibit hIAPP amyloid formation are indicated by a bold "Yes" in the "Inhibition" column, while peptides that rescue cells from hIAPP toxicity are indicated by a bold "Yes" in the "Rescue" column.

[0034] Fig.15 Graph showing the results of Thioflavin T binding assays when hIAPP was mixed with the indicated chicken and raccoon IAPP variants. Human IAPP was incubated with each indicated peptide at 37°C with shaking. The four vertical bars for each peptide represent the fluorescence after 10 minutes, 20 minutes, 25 minutes, and 30 minutes, respectively, from left to right. The data show the average of at least two experiments, and the error bars show the standard deviation between experiments.

[0035] Fig.16 is a graph showing the results of MTT viability assays comparing variant raccoon IAPP peptides. The leftmost black bar shows the average viability of cells alone. The left bar above each peptide identifier on the horizontal axis shows the average cell viability after addition of 12.8 μM of each designated IAPP peptide alone. The right bar above each peptide identifier on the horizontal axis shows the cell viability after hIAPP was mixed with the designated IAPP peptide (a mixture of hIAPP at a ratio of 1:1 to each designated IAPP peptide at 12.8 μM).

[0036] Fig.17 is a table listing several peptides based on truncations of the chicken IAPP sequence. Peptides that inhibit hIAPP amyloid formation are indicated by a bold "Yes" in the "Inhibition" column, while peptides that rescue cells from hIAPP toxicity are indicated by a bold "Yes" in the "Rescue" column.

[0037] Fig.18 is a graph showing the results of Thioflavin T binding assays when hIAPP was mixed with the indicated chicken IAPP variants. hIAPP was incubated with each indicated peptide at 37°C with shaking. The four vertical bars for each of the four peptides represent the fluorescence after 10 minutes, 20 minutes, 25 minutes, and 30 minutes, respectively, from left to right. The data show the average of at least two experiments, and the error bars show the standard deviation between experiments.

[0038] Fig.19AFM scans of truncated chicken and raccoon IAPP peptides are shown. In the scans depicted, the R1-23, R8-23, and R8-30 peptides did not inhibit the aggregation of hIAPP, while the R1-29, R1-27, C1-29, and C1-27 peptides did. Each sample contained 37 μM hIAPP and 75 μM of the indicated peptide. The samples were incubated at 37°C with shaking for 40 minutes. All scans show the raw data without flattening and are 10 μm x 10 μm.

[0039] Fig. 20 is a table listing several peptides based on mutations in the chicken IAPP sequence. Peptides that inhibit hIAPP amyloid formation are indicated by a bold "Yes" in the "Inhibition" column, while peptides that rescue cells from hIAPP toxicity are indicated by a bold "Yes" in the "Rescue" column.

[0040] Fig.21 is a graph showing the results of an MTT viability assay comparing variant chicken IAPP peptides. The leftmost black bar shows the average viability of individual cells. The left bar above each peptide identifier on the horizontal axis shows the average cell viability after addition of 12.8 μM hIAPP or chicken IAPP variants alone. The right bar above each peptide identifier on the horizontal axis shows the cell viability after hIAPP was mixed with chicken IAPP variants (a 1:1 ratio of hIAPP to 12.8 μM mixture of each designated IAPP peptide).

[0041] Fig. 22 Results of AFM scans of raccoon and chicken IAPP variants when mixed with hIAPP are shown. Each sample contained 37 μM hIAPP mixed with 37 μM of the indicated peptide. The samples were incubated at 37°C with shaking for 30 minutes, and each sample was then deposited on freshly cleaved mica. DETAILED DESCRIPTION

[0042] definition

[0043] As used herein, the following terms and variations thereof have the meanings given below, unless the context in which the term is used dictates a different meaning.

[0044] "About" and "approximately" refer to quantities within 10% of the referenced amount, unless the context of such usage indicates a different meaning. For example, but not limited to, "about 10" means 9-11, and "about 10%" means 9%-11%.

[0045] "Amyloid disease" refers to medical conditions caused by or associated with aggregates of peptides and / or proteins, particularly amylin, having a fibrillar morphology and a β-sheet secondary structure. Human IAPP can form oligomers or plaques, and such aggregates are associated in some cases with type II diabetes and Alzheimer's disease.

[0046] "Cytoprotection" refers to the ability to attenuate, mitigate or prevent cell damage or death, particularly exposure to the toxic effects of hIAPP. Cytoprotection can be measured in a manner known in the art, such as by cell viability and cytotoxicity assays.

[0047] "IAPP" refers to islet amyloid polypeptide found in various animals, particularly mammals and birds.

[0048] "IAPP peptide" refers to a peptide having one or more amino acid substitutions compared to human IAPP (SEQ ID NO: 1). The IAPP peptide may be truncated and preferably has a length of at least 70%, 73%, 75%, 80%, 85%, 90% or more compared to hIAPP. Preferably, the IAPP peptide has at least 80% sequence identity to hIAPP, such as 89%, 92%, 95% or up to 97% sequence identity.

[0049] For amyloid oligomers, fibers and aggregates, "inhibition" means slowing and / or preventing the formation of such oligomers, fibers and aggregates as compared to the formation of such materials in the absence of the substance causing such inhibition. Amyloid formation can be measured in a manner known in the art, such as by a thioflavin T binding assay. Preferably, the IAPP peptide inhibits the formation of IAPP aggregates by about 50% or more.

[0050] "Medical condition" means a condition that causes illness, discomfort and / or disability in a subject.

[0051] "Pharmaceutical effect" and "therapeutic effect" refer to the effect of restoring, correcting or changing the physiological function of the subject, including curing, alleviating, treating or preventing the medical condition of the subject. "Pharmaceutical composition" and "drug" are compositions with pharmaceutical effects.

[0052] "Treatment" refers to the act of alleviating, ameliorating, preventing and / or resolving a medical condition. Treatment may refer to prevention or treatment after the development of a medical condition requiring treatment.

[0053] The term "include" and variations of the term, such as "comprises" and "comprising" are not meant to exclude other additives, ingredients, integers or steps. The terms "a", "an" and "the" and similar references used herein should be understood to cover both the singular and the plural, unless their usage in context indicates otherwise. A range described as "between" two values ​​includes the values ​​shown.

[0054] IAPP peptide

[0055] IAPP peptides from other species

[0056] We compared the aggregation potential of naturally occurring IAPP peptides from various organisms and evaluated their interactions with human IAPP (hIAPP). In these studies, we unexpectedly found that several of these animal IAPP peptides showed a significant ability to inhibit hIAPP aggregation, prevent amyloid formation, and protect mammalian cells from hIAPP toxicity.

[0057] The amino acid sequence of the naturally occurring IAPP peptide we evaluated is shown in Figure 1 In the figure, sequence differences with human IAPP are shown in bold. Animal IAPP peptides identified as showing the potential to inhibit hIAPP aggregation are listed at the top of the figure, while those variants that lack inhibitory potential are listed at the bottom. Although IAPP peptides from cattle, degus, guinea pigs, horses, pigs, rats and sheep failed to inhibit the aggregation of human IAPP, we were surprised to find that IAPP from cats, dogs, chickens, polar bears, raccoons and seals was able to inhibit this aggregation when mixed with hIAPP. The sequences of these inhibitory IAPP peptides are shown in Table 1 below.

[0058] Table 1

[0059] type sequence SEQ ID NO. cat KCNTATCATQRLANFLIRSSNNLGAILSPTNVGSNTY 2 dog KCNTATCATQRLANFLVRTSNNLGAILSPTNVGSNTY 3 chicken KCNTATCVTQRLADFLVRSSSNIGAIYSPTNVGSNTY 4 Polar Bear KCNTATCATQRLANFLVRSGNLFGAILSPTNVGSNTY 5 Raccoon KCNTATCVTQRLANFLLRSSNNLGAILSPTNVGSNTY 6 seal KCNTATCATQRLANFLVRSSNNLGAILSPTNVGSNTY 7

[0060] As discussed in Examples 1-3 below, these peptides inhibited the aggregate formation of hIAPP ( Figure 1-3 ), and raccoon and chicken IAPP peptides also rescued living cells from the toxic effects of hIAPP ( Figure 4 ).

[0061] Weddell seal variant

[0062] Variants (mutations) of Weddell seal IAPP were prepared to determine their ability to inhibit hIAPP aggregation. Figure 7 Some of them were found to be able to inhibit the aggregation of hIAPP and / or protect cells from the toxicity of hIAPP. These sequences are shown in Table 2 below.

[0063] Table 2

[0064] name sequence SEQ ID NO. WS_R KCNTATCATQRLANFLVRSSNNFGAILSSTNVGSNTY 15 WS_RL KCNTATCATQRLANFLVRSSNNLGAILSSTNVGSNTY 16 WS_RP KCNTATCATQRLANFLVRSSNNFGAILSPTNVGSNTY 17 WS_LP KCNTATCATQRLANFLVHSSNNLGAILSPTNVGSNTY 18

[0065] Figure 8 Results of Thioflavin T binding assays when hIAPP was mixed with the indicated Weddell seal variants are shown. WS-RL (SEQ ID NO: 16) and WS-LP (SEQ ID NO: 18) IAPP peptides inhibited aggregation of hIAPP. WS-RL and WS-RP (SEQ ID NO: 17) also rescued cells from the toxicity of hIAPP in the MTT assay ( Fig.10 ). However, WS-LP (and WS-P) peptides were shown to be toxic to cells regardless of the addition of hIAPP.

[0066] Raccoon variant

[0067] Given that raccoon IAPP can inhibit the aggregate formation of hIAPP and can also rescue living cells from the toxic effects of hIAPP, a series of IAPP peptides based on the natural raccoon IAPP peptide sequence were synthesized and characterized for their ability to inhibit human IAPP amyloid formation and rescue cells from hIAPP toxicity. Fig.12 , 16 As shown in Figures 1 and 19, several IAPP peptides truncated from the C-terminus of the raccoon IAPP peptide were found to be able to both inhibit the aggregation of hIAPP and protect cells from the toxicity of hIAPP. Although the removal of amino acids from the N-terminus (SEQ ID NOs: 21 and 23) and the middle (SEQ ID NOs: 22, 24, and 25) of the full-length raccoon IAPP resulted in peptides that failed to inhibit the aggregation of hIAPP or reduce its cytotoxicity, the removal of up to 13 amino acids from the C-terminus of the full-length raccoon IAPP resulted in peptides that were able to both inhibit the aggregation of hIAPP and protect cells. Table 3 below lists truncated raccoon hIAPP peptides that have the ability to inhibit the formation of hIAPP aggregates and protect cells from hIAPP cytotoxicity.

[0068] Table 3

[0069] name sequence SEQ ID NO. R1-35 KCNTATCVTQRLANFLLRSSNNLGAILSPTNVGSN 26 R1-34 KCNTATCVTQRLANFLLRSSNNLGAILSPTNVGS 27 R1-33 KCNTATCVTQRLANFLLRSSNNLGAILSPTNVG 28 R1-32 KCNTATCVTQRLANFLLRSSNNLGAILSPTNV 29 R1-31 KCNTATCVTQRLANFLLRSSSNNLGAILSPTN 30 Rl-30 KCNTATCVTQRLANFLLRSSNNLGAILSPT 31 R1-29 KCNTATCVTQRLANFLLRSSNNLGAILSP 32 R1-28 KCNTATCVTQRLANFLLRSSNNLGAILS 33 R1-27 KCNTATCVTQRLANFLLRSSNNLGAIL 34 R1-26 KCNTATCVTQRLANFLLRSSNNLGAI 35 R1-25 KCNTATCVTQRLANFLLRSSNNLGA 36 R1-24 KCNTATCVTQRLANFLLRSSNNLG 37

[0070] While the corresponding native raccoon IAPP peptides showed some cytotoxicity when incubated with pancreatic cells, these truncated peptides showed almost no toxicity.

[0071] Additional peptides were created using modified (mutated) sequences from raccoon IAPP and analyzed for their ability to inhibit hIAPP aggregation. Fig.12 The sequence shown in showed strong inhibition of hIAPP amyloid formation.

[0072] Table 4

[0073] name sequence SEQ ID NO. Rac_V8A KCNTATCATQRLANFLLRSSNNLGAILSPTNVGSNTY 42 Rac_N13D KCNTATCVTQRLADFLLRSSNNLGAILSPTNVGSNTY 43 Rac_L16V KCNTATCVTQRLANFLVRSSNNLGAILSPTNVGSNTY 44 Rac_L22I KCNTATCVTQRLANFLLRSSNNIGAILSPTNVGSNTY 45 Rac_L26Y KCNTATCVTQRLANFLLRSSNNLGAIYSPTNVGSNTY 46

[0074] Rac-L26Y (SEQ ID NO: 46) stood out for its ability to inhibit hIAPP fibril formation and rescue cells from hIAPP toxicity while displaying minimal intrinsic toxicity.

[0075] Chicken variant

[0076] Given that chicken IAPP can inhibit the aggregation of hIAPP and rescue living cells from the toxic effects of hIAPP, a series of IAPP peptides based on the natural chicken IAPP peptide sequence were synthesized and characterized for their ability to inhibit the formation of human IAPP amyloid and rescue cells from the toxic effects of hIAPP. Fig.18 , 19 As shown in Figures 2 and 21, several IAPP peptides truncated from the C-terminus of the chicken IAPP peptide were found to inhibit the aggregation of hIAPP and / or protect cells from the toxicity of hIAPP. Removing amino acids from the N-terminus of the full-length chicken IAPP resulted in peptides that could not inhibit the aggregation of hIAPP or reduce its cytotoxicity, while peptides truncated to a length of less than 24 amino acids lost the ability to inhibit amyloid. However, removing up to 13 amino acids from the C-terminus of the full-length chicken IAPP resulted in peptides that could inhibit the aggregation of hIAPP and / or protect cells from the cytotoxicity of hIAPP. These peptides are shown in Table 5 below.

[0077] Table 5

[0078]

[0079]

[0080] While the corresponding native chicken IAPP peptide showed some cytotoxicity when incubated with pancreatic cells, these truncated peptides showed little toxicity.

[0081] Additional peptides were created using sequences modified from chicken IAPP and analyzed for their ability to inhibit hIAPP aggregation. The sequences in Table 6 showed strong inhibition of hIAPP amyloid formation

[0082] Table 6

[0083] name sequence SEQ ID NO. Ch_V8A KCNTATCATQRLADFLVRSSSNIGAIYSPTNVGSNTY 65 Ch_V16L KCNTATCVTQRLADFLLRSSSNIGAIYSPTNVGSNTY 66 Ch_I22L KCNTATCVTQRLADFLVRSSSNLGAIYSPTNVGSNTY 67 Ch_Y26L KCNTATCVTQRLADFLVRSSSNIGAILSPTNVGSNTY 68

[0084] Ch-I22L (SEQ ID NO: 67) was able to inhibit the formation of hIAPP fibers and rescue cells from the toxicity of hIAPP while showing minimal intrinsic toxicity (see Fig.15 , 21 and 22).

[0085] Measuring the effects of IAPP peptides

[0086] Any of a variety of assays known in the art can be used to assess the ability of IAPP peptides to inhibit hIAPP aggregation and / or protect cells from hIAPP toxicity. Thioflavin T (ThT) binding is a technique for real-time identification of amyloid formation. It is known that human IAPP binds to Thioflavin T during aggregation and amyloid formation, and when bound to amyloid fibrils, ThT is excited at 450 nanometers and emits a strong fluorescence signal at about 482 nanometers. ThT fluorescence is linearly related to the concentration of amyloid in the sample and can therefore be used to determine the amount of aggregation in the sample. Therefore, when these substances are mixed with human IAPP under conditions known to cause hIAPP to form aggregates, this technique can be used to identify substances with the potential to inhibit amyloid. Other techniques can also be used to determine the extent of aggregation, such as atomic force microscopy (AFM), which can provide information about particle size, shape, and substructure at nanometer resolution. In the above assays and other assays that can be used by those skilled in the art, by measuring the difference between hIAPP and hIAPP bound to IAPP peptides, a significant inhibitory effect can be determined using a t-test. Significant results were shown when the t-test value was <0.05.

[0087] Cell protection can also be measured by a variety of assays known in the art. One such assay is the MTT assay, which is a colorimetric assay for assessing cellular metabolic activity. NAD(P)H-dependent cellular oxidoreductases within the intracellular compartments of the cell reduce the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to an insoluble form of formazan, which has a purple color. The reduction of MTT (and other tetrazolium dyes) is dependent on the metabolic activity of the cell, so the disappearance of the color during the MTT assay indicates low metabolic activity and is therefore an indicator of cell damage and death.

[0088] Pharmaceutical preparations

[0089] IAPP peptides can be formulated into pharmaceutical compositions (medicaments) and administered in a manner known in the art, including intramuscular, intravenous and subcutaneous administration. Depending on the route of administration, the pharmaceutical composition can be formulated into a liquid, powder or other solid, or a gel. When the composition is in powder form, the IAPP peptide can be in the form of a salt, such as acetate, etc. The pharmaceutical composition may include one or more pharmaceutically acceptable carriers and / or other pharmaceutically acceptable excipients, such as for stabilizing the composition and / or delivering the composition to a subject. The excipients of the present pharmaceutical composition may include appropriate additives, such as pharmaceutically effective carriers (i.e., sterile water, water and saline, etc.), buffers, neutralizers, stabilizers, humectants, tackifiers, chemical stabilizers, thickeners, diluents and / or solvents. Examples of excipients in some embodiments include, but are not limited to, alcohols and polyethylene glycols, glycerol, waxes, water, deionized water, fatty acid esters, etc., mixtures and combinations thereof. Preparations suitable for parenteral administration (e.g., administered by intravenous, intramuscular, intradermal and subcutaneous routes) include aqueous and non-aqueous isotonic sterile injections.

[0090] Application of IAPP peptide

[0091] IAPP peptides can be used to inhibit IAPP aggregation or protect cells, for example as described in the examples below. In one embodiment, IAPP peptides are administered to cells in vitro to protect cells from contact with amyloid fibers, such as aggregates of hIAPP, which are found to induce cytotoxicity when applied externally and when secreted from cells. The IAPP peptides of the present invention can also be administered to subjects to reduce the aggregation of IAPP in vivo. The IAPP peptides of the present invention can be particularly useful for treating humans or other mammalian subjects suffering from amyloid diseases, such as diabetes. In one embodiment of the present invention, the IAPP peptides of the present invention that can both inhibit hIAPP aggregation and protect cells from the toxic effects of hIAPP can be administered to subjects to treat amyloid diseases.

[0092] For example, peptides derived from human IAPP, such as ANFLVH, can inhibit the formation of amyloid fibers and reduce cytotoxicity. They have been shown to improve fasting blood glucose levels and glucose tolerance in subjects after injection (Wijesekara et al., Diabetes, Obesity and Metabolism 17: 1003-1006, 2015). The IAPP peptide pramlintide has also been used to treat human diabetes. This peptide contains three amino acid substitutions found in rat IAPP. However, pramlintide is more susceptible to amyloidosis than the IAPP peptides of the present invention and has no cytoprotective effect. Figure 5The AFM scans shown show that raccoon IAPP alone did not aggregate, whereas pramlintide formed amyloid fibrils under the same conditions. Raccoon IAPP peptide also prevented the aggregation of hIAPP, whereas pramlintide was unable to do so under the same conditions. Unlike raccoon and chicken IAPP, pramlintide was also toxic to cells and had no ability to protect cells from the toxic effects of hIAPP (see Figure 6 ).

[0093] The IAPP peptides can be administered to a subject by means known in the art, such as by parenteral administration, for example, by intramuscular, intravenous or subcutaneous administration. In one embodiment, the IAPP peptide composition can be directly administered to a site where aggregated IAPP is found, such as the pancreas, particularly the islets of Langerhans. Amylin oligomers and plaques are also found in blood vessels, peripheral vascular spaces, and brain tissue (parenchyma), so the IAPP peptide composition can also be injected or applied to these organs or compartments to administer the IAPP peptides of the present invention to a subject.

[0094] Depending on the particular needs of the individual subject involved, the peptides of the present invention can be administered in various doses to provide effective treatment for amyloid disease. Preferably, a dose of about 1 microgram (mcg) to about 500 micrograms, such as about 2mcg, 5mcg, 7mcg, 10mcg, 15mcg, 20mcg, 30mcg, 40mcg, 50mcg, 60mcg, 70mcg, 80mcg, 90mcg, 100mcg, 120mcg, 150mcg, 170mcg, 200mcg, 220mcg, 250mcg, 270mcg, 300mcg, 320mcg, 350mcg, 370mcg, 400mcg, 420mcg, 450mcg or 470mcg can be administered to the subject. The amount of the IAPP peptide of the present invention to be administered, for example, can be 0.1mcg / kg / day, 0.15mcg / kg / day, 0.2mcg / kg / day, 0.25mcg / kg / day, 0.3mcg / kg / day, 0.4mcg / kg / day, 0.5mcg / kg / day, 0.7mcg / kg / day, 0.9mcg / kg / day, 1.0mcg / kg / day, 1.2mcg / kg / day, 1.5mcg / kg / day, 1.7mcg / kg / day, 2.0mcg / kg / day, 2.2mcg / kg / day, 2.5mcg / kg / day, 3.0mcg / kg / day, 3.5mcg / kg / day, 4.0mcg / kg / day, 4.5mcg / kg / day or 5.0mcg / kg / day. Factors such as the aggregation inhibition activity of the selected peptide, the half-life of the peptide, the physiological characteristics of the subject, the extent or nature of the subject's condition, and the method of administration will determine the effective amount of the selected peptide, which is known to those skilled in the art. In general, the initial dose will be modified to determine the optimal dose for treating a particular subject. It may be necessary to administer repeated doses of the peptide of the present invention over a longer period of time.

[0095] The effective amount of any embodiment of the present invention is determined by methods known to pharmacologists and clinicians of ordinary skill in the art. For example, an animal model can be used to determine the applicable dose for a patient. Many models of diabetes and other amyloid diseases are known. For example, Wijesekara et al. (Diabetes, Obesity and Metabolism 17: 1003-1006, 2015) disclose a transgenic mouse model of type 2 diabetes that has been used to evaluate IAPP-derived peptides.

[0096] As known to those skilled in the art, a very low dose of a peptide, i.e., a peptide found to be minimally toxic in animals (e.g., 1 / 10×LD10 in mice) can be administered to a patient first, and if that dose is found to be safe, the patient can be treated with a higher dose. The therapeutically effective amount of one of the peptides of the invention for treating an amyloid disease can then be determined by administering increasing amounts of the peptide to a patient suffering from the disease until the patient's symptoms are observed or reported by the patient as being reduced or eliminated.

[0097] The blood concentration of the peptides of the present invention can be determined by conventional biological and chemical detection methods, and these blood concentrations can be matched with the administration route and half-life of the selected peptides. Then, the blood concentration and administration route can be used to establish a therapeutically effective amount of a pharmaceutical composition comprising one of the peptides of the present invention for preventing and / or treating amyloid diseases.

[0098] It should be noted that raccoon and chicken IAPP were found to prevent aggregation of hIAPP in the presence of human insulin and are therefore safe for use in conjunction with the treatment of diabetes. Both raccoon and chicken IAPP were also less prone to aggregation than pramlintide, another diabetes treatment.

[0099] Example

[0100] Example 1: Thioflavin T assay with hIAPP inhibitors from other species

[0101] To identify IAPP peptides with inhibitory potential on hIAPP aggregation, Figure 1 The indicated peptides were mixed with hIAPP at a molar ratio of 2:1 of animal peptide to hIAPP and incubated under conditions known to promote hIAPP aggregation and fibril formation. hIAPP alone or mixed with animal IAPP was transferred to a glass tube and HFIP was removed under rapid vacuum. The resulting peptide samples were dissolved in 20 mM Tris buffer, pH 7.4.

[0102] 37 μM human IAPP was mixed with 75 μM of each designated animal IAPP. The samples were shaken at 200 rpm for 40 minutes at 37°C to induce aggregation. At the designated time points, 17 μL aliquots of each sample were mixed with 663 μL of 50.0 μM Thioflavin T in 20 mM Tris buffer (pH 7.4). The fluorescence emission of Thioflavin T was then recorded at 488 nm using a Hitachi F-7000 fluorescence spectrophotometer.

[0103] After 40 minutes, the samples were monitored for their ability to bind Thioflavin T (see Figure 2), and its ability to form fibers was identified using atomic force microscopy.

[0104] Example 2: Atomic force microscopy of hIAPP inhibitors from other species

[0105] Direct testing using AFM Figure 1 The amyloid inhibitory potential of each animal IAPP peptide shown in . As described in Example 1, hIAPP samples containing or not containing animal IAPP were prepared and then incubated at 37°C for 40 minutes with shaking. After incubation, 17 μL of each sample was precipitated on freshly cut mica. The samples were incubated at room temperature for 5 minutes and then washed with 200 μL of sterile water. After drying, the samples were scanned using an MFP-3D atomic force microscope (Asylum Research) set to A / C mode and a 240 μm silicon cantilever (Olympus).

[0106] Under these conditions, human IAPP forms high-density fibrils when deposited on mica and scanned by AFM. It is known that many animal IAPP variants also form fibrils and produce amyloid plaques when scanned by AFM. When mixed with hIAPP, animal IAPP peptides from cattle, degus, dolphins, guinea pigs, horses, pigs, rats and sheep have no effect on the formation of hIAPP fibrils, or seem to promote the formation of fibrils together with hIAPP. Six IAPP variants were found to inhibit the formation of hIAPP fibrils, among which chickens, cats, dogs, polar bears, raccoons and seals all showed a significant ability to prevent fiber formation. This is true despite the fact that all these IAPP peptides (except polar bear IAPP) are known to aggregate and form fibrils under these or similar conditions.

[0107] Example 3: Cell viability assay using hIAPP inhibitors from other species

[0108] In order to test the ability of animal IAPP variants to rescue living cells from the toxic effects of hIAPP, survival and cytotoxicity tests were performed. In order to test cell survival, the MTT colorimetric method was used, which measures the conversion of yellow tetrazolium salts into purple formazan crystals under the catalysis of mitochondrial reductase. Cell survival studies were performed with RIN-m cells (ATCC, CRL-2057). Equal numbers of RIN-m cells were plated in triplicate and incubated overnight in 96-well plates. The next day, fresh RPMI-1640 with phenol red supplemented with 10% FBS was added to the cells. Hexafluoroisopropanol (HFIP) was removed from each human and animal IAPP using a centrivap concentrator (LabOnco). All IAPP peptide samples were resuspended in RPMI-1640 containing 10% FBS. In order to ensure uniform resuspension, the vials containing each resulting IAPP were scraped six times with a pipette tip and vortexed (Vortex Genie mixer) for 15 seconds. The entire process from drying each IAPP peptide to adding each IAPP peptide to the cells was unified to ensure that each sample was incubated with each IAPP peptide for an equal time. The IAPP peptides were added to the cells and incubated at 37°C for 46 hours. After incubation, the medium in each well was replaced with fresh DMEM / F-12 without phenol red. MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium bromide) was added to each well and incubated at 37°C for 2 hours. The formazan crystals formed at the bottom of the well were resuspended in solubilization buffer (20% SDS and 50% dimethylformamide). The absorbance in each well was measured at 570nm using a Multiskan FC microplate photometer (Thermos Fisher Scientific). The culture medium was obtained from ATCC. All incubations were performed in a water-jacketed incubator (Shell Lab) at 37°C and 5% carbon dioxide.

[0109] The MTT viability assay was used to measure the cell viability of RIN-m cells after the addition of hIAPP alone, each animal IAPP peptide alone, and hIAPP mixed with each animal IAPP peptide (results are shown in Figure 5). RIN-m cells alone were used as a control and set to 100% cell viability. Addition of 12.8 μM human IAPP consistently resulted in a decrease in cell viability to 55+ / -5%. Addition of 12.8 μM raccoon, cat, seal, polar bear, and pig IAPP variants alone resulted in an average decrease in cell viability of 20-25%, while the addition of chicken and rat IAPP had an improved effect on cell viability. Mixing hIAPP and raccoon IAPP variants in a 1:1 ratio (12.8 μM concentration of each IAPP) protected RIN-m cells from the toxic effects of hIAPP. Addition of raccoon IAPP to hIAPP increased cell viability from 55% to an average of 72% (p=0.005705). Addition of chicken IAPP variants to hIAPP increased cell viability to an average of 76% (p=0.013556). Adding cat and seal IAPP variants to hIAPP also increased cell survival to about 62 percent, but the results were more varied. Polar bear, rat and pig IAPP variants did not protect RIN-m cells from the toxic effects of hIAPP.

[0110] Example 4: Weddell seal IAPP peptide variants

[0111] use Figure 7 The indicated variants of Weddell seal IAPP were subjected to the Thioflavin T binding assay. Human IAPP (37 μM) was mixed with each indicated Weddell seal variant (75 μM) and incubated at 37°C with shaking at 200 rpm for 30 minutes. The results are shown in Figure 8 The Weddell seal IAPP peptide was also subjected to atomic force microscopy as described in Example 2. These results, such as Fig. 9 As shown, the WS_RL and WS_LP variants were shown to be potent inhibitors of hIAPP fibril formation.

[0112] Example 5: Truncated Raccoon IAPP Peptide Variants

[0113] Thioflavin T binding assay is performed using Fig.11 Human IAPP was mixed with the raccoon variant and incubated at 37°C with shaking. The results are shown in Fig.12 and 13 The R1-27, R1-29, and R1-30 variants inhibited the aggregation of hIAPP and also rescued cells from hIAPP-induced cytotoxicity in the MTT viability assay (see Fig.16 ).

[0114] Example 6: Mutated Raccoon IAPP Peptide Variants

[0115] Thioflavin T binding assay is performed using Fig.10Human IAPP was mixed with each of the indicated raccoon variants and incubated at 37°C with shaking. The results are shown in Fig.15 The Rac_V8A, Rac_N13D, Rac_L16V, Rac_L22I, and Rac_L26Y variants inhibited the aggregation of hIAPP, and Rac_L26Y also increased cell survival in the MTT viability assay in the presence of hIAPP, as shown in Figure 2. Fig.16 shown.

[0116] Example 7: Truncated chicken IAPP peptide variants

[0117] Thioflavin T binding assay is performed using Fig.17 The human IAPP was mixed with each of the chicken IAPP variants and incubated at 37°C with shaking. The results are shown in Fig.18 The C1-27 and C1-29 variants inhibited the aggregation of hIAPP and also rescued cells from hIAPP-induced cytotoxicity in the MTT viability assay (see Fig.21 Although the C1-29 peptide prevented ThT binding, amyloid fibrils were formed when this peptide was used for AFM scanning (as described in Example 2), so Fig.13 The peptide was not able to inhibit hIAPP aggregation. However, it was able to protect cells in the MTT assay, so it is believed that it can inhibit the formation of toxic oligomers, while having little effect on inhibiting the formation of fibrils (which are less toxic and less likely to bind to ThT).

[0118] Example 8: Mutated chicken IAPP peptide variants

[0119] Thioflavin T binding assay is performed using Fig.14 The human IAPP was mixed with each of the chicken IAPP variants and incubated at 37°C with shaking. The results are shown in Fig.15 Ch_V16L, Ch_I22L and Ch_Y26L inhibited the aggregation of hIAPP and also rescued cells from hIAPP-induced cytotoxicity in the MTT viability assay (see Fig.21 ).

[0120] The term "include" and variations of the term, such as "comprises" and "comprising" are not meant to exclude other additives, ingredients, integers or steps. The terms "a", "an" and "the" and similar references used herein should be understood to cover both the singular and the plural, unless their usage in context indicates otherwise. A range described as "between" two values ​​includes the values ​​shown.

[0121] Although the present invention has been described in considerable detail with reference to certain preferred embodiments, other embodiments are also possible. For example, the steps disclosed for the method are not intended to limit or indicate that each step is essential to the method, but are merely exemplary steps. Therefore, the scope of the appended claims should not be limited to the description of the preferred embodiments contained in this disclosure.

[0122] Reference herein to ranges of values ​​is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated into the specification as if it were individually disclosed herein. For example, "about 10" includes the exact disclosure of 10. All references cited herein are incorporated by reference in their entirety.

Claims

1. An IAPP peptide represented by an amino acid sequence selected from the group consisting of SEQ ID NOs: 42-46.

2. A pharmaceutical composition comprising the IAPP peptide of claim 1 and one or more pharmaceutically acceptable excipients.

3. Use of the IAPP peptide according to claim 1 in the preparation of a medicament for treating type 2 diabetes.

4. The use according to claim 3, wherein: The IAPP peptide is SEQ ID NO:46.